Moderna, Inc. (MRNA) shares surged 5.05% in Tuesday's pre-market trading session following the company's announcement of a significant regulatory milestone. The biotechnology firm has filed an application with the U.S. Food and Drug Administration (FDA) for the review of its Spikevax formula, which targets the SARS-CoV-2 variant LP.8.1.

This move demonstrates Moderna's continued efforts to adapt its COVID-19 vaccine to emerging variants, potentially positioning the company to maintain its strong presence in the global vaccine market. Investors appear to be reacting positively to this development, seeing it as a sign of Moderna's ongoing innovation and potential for future revenue streams.

In related news, Moderna also announced its upcoming participation in two major healthcare conferences: the Jefferies Global Health Care Conference on June 5th and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th. These presentations may provide further insights into the company's pipeline and strategic direction, potentially sustaining investor interest in the coming weeks.